Skip to main content

Table 1 Distribution of benign breast features and other characteristics by fibroadenoma status

From: Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease

Characteristic Status, n (%)a   P valueb
No fibroadenoma
2047 (53.2)
Fibroadenoma
1798 (46.8)
 
Age at benign biopsy, years    < 0.001
  < 40 387 (18.9) 573 (31.9)  
 40–49 692 (33.8) 582 (32.4)  
 50–59 577 (28.2) 374 (20.8)  
 60–69 249 (12.2) 164 (9.1)  
 70+ 142 (6.9) 105 (5.8)  
Biopsy type    < 0.001
 Excisional 826 (40.4) 536 (30.8)  
 Core needle 1221 (59.6) 1262 (70.2)  
Apocrine metaplasia    < 0.001
 Absent 1202 (58.7) 1401 (82.3)  
 Present 845 (41.3) 301 (17.7)  
Ductal hyperplasia    < 0.001
 Absent 1272 (62.1) 1365 (80.6)  
 Present 775 (37.9) 329 (19.4)  
Lobular hyperplasia    0.008
 Absent 2012 (98.3) 1662 (99.3)  
 Present 34 (1.7) 11 (0.7)  
Calcifications    < 0.001
 Absent 1209 (59.1) 1229 (70.8)  
 Present 837 (40.9) 507 (29.2)  
Cysts    < 0.001
 Absent 970 (47.4) 1339 (78.9)  
 Present 1076 (52.6) 359 (21.1)  
Duct ectasia    < 0.001
 Absent 1652 (80.7) 1546 (91.0)  
 Present 394 (19.3) 152 (9.0)  
Fibrosis    < 0.001
 Absent 648 (31.7) 1031 (63.8)  
 Present 1397 (68.3) 586 (36.2)  
Intraductal papilloma    < 0.001
 Absent 1662 (81.2) 1629 (96.1)  
 Present 385 (18.8) 66 (3.9)  
Sclerosing adenosis    < 0.001
 Absent 1416 (69.2) 1404 (82.7)  
 Present 630 (30.8) 294 (17.3)  
Columnar alterations    < 0.001
 Absent 1302 (63.6) 1439 (84.7)  
 Present 744 (30.8) 259 (15.3)  
Radial scar    < 0.001
 Absent 1975 (96.5) 1665 (98.6)  
 Present 71 (3.5) 23 (1.4)  
Dupont and Page criteria    < 0.001
 Nonproliferative disease 868 (42.4) 1325 (73.7)  
 Proliferative disease without atypia 1054 (51.5) 450 (25.0)  
 Proliferative disease with atypia 125 (6.1) 23 (1.3)  
Developed breast cancer    < 0.001
 No 1902 (92.9) 1722 (95.8)  
 Yes 145 (7.1) 76 (4.2)  
  1. aNumbers may not sum to the total number of patients if features could not be assessed on biopsy
  2. bχ2 test comparing distribution of features across absence or presence of fibroadenoma on biopsy